Monopar Therapeutics Inc.
NASDAQ:MNPRBiotechnology
+$1.58 today
- Market cap
- $479.46M
- Beta
- 1.54
- P/E (TTM)
- -37.6
- EPS (TTM)
- -$1.76
Volume 0.10M
Average 0.17M
MNPR Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Monopar Therapeutics Inc.NASDAQ: MNPR
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$93.4M, compared with -$78.42M a year earlier.
Context
- Retained earnings amounted to 67.7% of total assets at the end of Q1 FY2026, down 74.7 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -19.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (89.51M) USD
- Year-over-year change
- -18.1%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (89.51M) | -18.1% |
| FY2024 | 2024-12-31 | (75.79M) | -25.9% |
| FY2023 | 2023-12-31 | (60.21M) | -16.2% |
| FY2022 | 2022-12-31 | (51.8M) | -25.5% |
| FY2021 | 2021-12-31 | (41.29M) | — |
Retained Earnings vs competitors
How MNPR compares with its peers on the latest reported figures
- Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -19.1% is the 8th highest of 11, against a peer median of -13.8%.
- Retained earnings amounts to 67.7% of total assets for MNPR, versus a peer median of 317.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$93.4M USD | -19.1% | — | 67.7% | |
| Jun 2026 | -$387.33M USD | +2.8% | — | 964.5% | |
| Dec 2025 | -€435.36M EUR | -12.7% | — | 694.4% | |
| Mar 2026 | -$449.49M USD | -17.9% | — | 219.1% | |
| Mar 2026 | -$740.74M USD | -13.6% | — | 415.4% | |
| Sep 2026 | -$940.91M USD | -42.9% | — | 186.1% | |
| Jun 2026 | -$946.6M USD | -20.9% | — | 130.6% | |
| Mar 2026 | -$960.58M USD | -29.5% | — | 147.2% | |
| Sep 2026 | -$1.01B USD | -13.9% | — | 85.8% | |
| Mar 2026 | -$1.28B USD | -5.8% | — | 588.0% | |
| Mar 2026 | -$1.67B USD | -8.9% | — | 572.5% | |
| Peer median (excluding MNPR) | — | -13.8% | — | 317.2% | |
Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Monopar Therapeutics Inc.
NASDAQ:MNPR
Intrinsic Alpha fair value
Locked
Current Price
$70.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.